Captor Therapeutics Spolka Akcyjna (BST:60Q)

Market Cap	92.69M +84.3%
Revenue (ttm)	466.65K -81.9%
Net Income	-10.30M
EPS	-1.80
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	15.04
Previous Close	14.98
Day's Range	14.34 - 15.12
52-Week Range	8.42 - 20.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 19, 2026

About BST:60Q

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics. It develops viadrudomide, which is in a Phase 1 clinical trial for hepatocellular carcinoma (HCC), lung cancer, and rare cancers; vratito...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 82
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: 60Q

Financial Performance

In 2025, BST:60Q's revenue was 4.66 million, a decrease of -70.55% compared to the previous year's 15.83 million. Losses were -42.00 million, 9.29% more than in 2024.

Financial numbers in PLN

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 10, 2026

Data Sources Report a data error